R&D Pipeline Overview

Through in-licensing from either big pharma/biotech companies or academic institutions, we have established a robust and science-driven portfolio that targets the underlying causes of the various orphan diseases with few or no approved options. Our focus is on first-in-class or best-in-class therapeutics that will truly bring meaningful and/or life-saving benefits to patients. We are also leveraging sponsored collaboration and research with universities to help de-risk potential projects before their adoption into our pipeline.

Exploratory

Animal POC

IND Enabling

Phase 1

Phase 2

Phase 3

Peptide

Monoclonal Antibody

ERT

Monoclonal Antibody

Animal POC

Exploratory

IND Enabling

Phase I

Phase II

Phase III

Monoclonal Antibody

Exploratory

Animal POC

IND Enabling

Phase I

Phase II

Phase III

Monoclonal Antibody

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

Peptide

Exploratory

Animal POC

IND Enabling

Phase I

Phase II

Phase III

3

2

1

Undisclosed

LM-014

Enzyme Replacement

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

Undisclosed

LM-070

Enzyme Replacement

Exploratory

Animal POC

Phase I

IND Enabling

Phase II

Phase III

LM-070

1. Received Orphan Drug Designation (ODD) from both FDA & European Commission.

2. Received Rare Pediatric Designation (RPD) from FDA.

3. Received Fast Track Designation (FTD) from FDA.

Treating Orphan Diseases With Few or No Options.

map.png

Redwood City, CA, USA

map.png

Taipei, Taiwan

©2020 BY LIFEMAX HEALTHCARE INTERNATIONAL